This concept, that Wnt signalling is not 100% activated when Apc is mutated in cancer cells, reveals a therapeutic window whereby targeting the Wnt receptor can still reduce the level of Wnt signalling even in cells which have mutations in Apc [78]. The gene discussed is FZD5; the disease is cancer.